News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Moomoo Market update
The article provides information related to Parabilis Medicines (PBLS) stock options chain, including quotes and news. The content itself is not available in the provided input.
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Parabilis Medicines, Inc. reported its Q2 2026 results, showing a significant increase in cash and cash equivalents to over $1.1 billion. This boost follows its June 2026 IPO, which generated $787.9 million in net proceeds, and a $50.0 million upfront payment from its collaboration …
The article is a brief financial news item from Investing.com, reporting on a Form 8K filing by Parabilis Medicines for August 13th. It provides no further details beyond stating the filing occurred on that date.
Parabilis Medicines, Inc. (PBLS) reported its Q2 revenue as $148,000. The company, a clinical-stage biopharmaceutical firm, focuses on developing transformative medicines for "undruggable" protein targets using its proprietary Helicon platform. Analysts currently have a "BUY" consensus for PBLS with an average target price of …
Parabilis Medicines reported a narrower Q2 net loss of $2.32 per share, with revenue reaching $148,000. Following this news, the company's shares experienced a rise in pre-bell trading. Parabilis Medicines, formerly FOG Pharmaceuticals, is a clinical-stage biopharmaceutical company focused on developing transformative medicines for …
Parabilis Medicines reported its second quarter 2026 financial results, highlighting significant progress in advancing zolucatetide for Wnt/β-catenin-driven diseases and expanding its Helicon™ platform through a collaboration with Regeneron. The company ended the quarter with a strong financial position of $1.1 billion in cash, cash …
Parabilis Medicines (PBLS) is a clinical-stage biopharmaceutical company with a market cap of US$4.6 billion. The company recently completed a record-breaking biotech IPO, raising substantial capital to fund a pivotal Phase 3 cancer therapy trial and expand its Helicon platform. Despite significant capital raises …
This article provides a stock quote and related news for Parabilis Medicines, Inc. (PBLS). It includes current trading information, performance data, and recent news headlines highlighting the company's IPO success and insider stock purchases, indicating significant interest and investment in the biotech firm.
FMR LLC has filed a Schedule 13G, disclosing a passive ownership stake of 10,292,735 shares, representing 8.5% of Parabilis Medicines Inc.'s outstanding common stock. Both FMR LLC and Abigail P. Johnson, a reporting person, hold sole dispositive power over these shares, with FMR LLC …
Search by ticker symbol or company name and select a result to open its chart.